Indian pharmaceutical sector is likely to gain, rather than being impacted, as the new US President Donald Trump aims to reduce drug prices since the country’s generic medicines are already affordable. Considering the fact that India offers a low-cost innovation and manufacturing hub and India-made generics sometimes cost almost one-tenth of branded drugs sold in the US, we are likely to be least affected by the anticipated policy changes. Trump wants American companies to manufacture domestically and sell products at US prices. Likewise, to fill in the void of Obamacare, “he will not mind import of quality medicines from India at affordable prices.’’ Indian pharma industry has for decades contributed significantly to contain and bring down the healthcare costs in the US by supplying high-quality yet affordable generic drugs to the country. With India now emerging as a leading global supplier of biosimilars, biopharma companies are well-placed to address the unmet need for more affordable versions of biologic products around the world, including the US.

(The Hindu)